About Critical Outcome T (OTCMKTS:COTQF)
Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The companys proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Its lead compound is COTI-2, a novel small molecule activator of misfolded mutant p53 proteins, which is in Phase I clinical trial for the treatment of gynecologic cancers, including ovarian, cervical, and endometrial cancers. The company also develops drug candidates for the treatment of acute myelogenous leukemia, colorectal cancer, small cell lung cancer, multiple sclerosis, and Alzheimers disease; and HIV integrase inhibitors. Critical Outcome Technologies Inc. was founded in 1999 and is based in London, Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book3.76
Return on Equity-216.27%
Return on Assets-94.74%
Critical Outcome T (OTCMKTS:COTQF) Frequently Asked Questions
What is Critical Outcome T's stock symbol?
Critical Outcome T trades on the OTCMKTS under the ticker symbol "COTQF."
How were Critical Outcome T's earnings last quarter?
Who are some of Critical Outcome T's key competitors?
Some companies that are related to Critical Outcome T include Repros Therapeutics (RPRX), Apricus Biosciences (APRI), Bio-Path (BPTH), IntelliPharmaCeutics Intl (IPCI), Interpace Diagnostics Group (IDXG), Valeritas (VLRX), Biocept (BIOC), Kitov Pharmaceuticals (KTOV), Aviragen Therapeutics (AVIR), HTG Molecular Diagnostics (HTGM), Sonoma Pharmaceuticals (SNOA), Eleven Biotherapeutics (EBIO), Eyegate Pharmaceuticals (EYEG), Anthera Pharmaceuticals (ANTH), Orexigen Therapeutics (OREX), RegeneRx Biopharmaceuticals (RGRX), Auris Medical (EARS) and Sevion Therapeutics (SVON).
How do I buy Critical Outcome T stock?
Shares of Critical Outcome T can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Critical Outcome T's stock price today?
One share of Critical Outcome T stock can currently be purchased for approximately $0.79.
How big of a company is Critical Outcome T?
Critical Outcome T has a market capitalization of $13.19 million. The company earns $-4,670,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Critical Outcome T employs 7 workers across the globe.
How can I contact Critical Outcome T?
Critical Outcome T's mailing address is 700 Collip Circle Suite 213, London A6, N6G 4X8. The company can be reached via phone at 519-858-5157 or via email at [email protected]
MarketBeat Community Rating for Critical Outcome T (COTQF)MarketBeat's community ratings are surveys of what our community members think about Critical Outcome T and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Critical Outcome T (OTCMKTS:COTQF) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Critical Outcome T (OTCMKTS:COTQF) Earnings History and Estimates Chart
Critical Outcome T (OTCMKTS COTQF) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Critical Outcome T (OTCMKTS:COTQF) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.3 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS
Dividend History for Critical Outcome T (OTCMKTS:COTQF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Critical Outcome T (OTCMKTS COTQF)
No insider trades for this company have been tracked by MarketBeat.com
Critical Outcome T (OTCMKTS COTQF) News Headlines
Critical Outcome T (OTCMKTS:COTQF) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Critical Outcome T (OTCMKTS COTQF) Stock Chart for Saturday, December, 16, 2017